المؤلفون: Obers, Andreas¹ (AUTHOR), Poch, Tobias¹ (AUTHOR), Rodrigues, Grace² (AUTHOR), Christo, Susan N.¹ (AUTHOR), Gandolfo, Luke C.^1,3,4 (AUTHOR), Fonseca, Raissa¹ (AUTHOR), Zaid, Ali¹ (AUTHOR), Kuai, Joey En Yu¹ (AUTHOR), Lai, Hongjin^1,5 (AUTHOR), Zareie, Pirooz¹ (AUTHOR), Yakou, Marina H.⁶ (AUTHOR), Dryburgh, Lachlan¹ (AUTHOR), Burn, Thomas N.¹ (AUTHOR), Dosser, James¹ (AUTHOR), Buquicchio, Frank A.^7,8 (AUTHOR), Lareau, Caleb A.^7,8 (AUTHOR), Walsh, Calum¹ (AUTHOR), Judd, Louise¹ (AUTHOR), Theodorou, Maria Rafailia⁹ (AUTHOR), Gutbrod, Katharina¹⁰ (AUTHOR)

المصدر: Immunity (10747613). Nov2024, Vol. 57 Issue 11, p2615-26263. 23649p.

مصطلحات موضوعية: *INTERLEUKIN-2, *TRANSFORMING growth factors-beta, *TRANSFORMING growth factors, *T cells, *IMMUNOLOGIC memory

Alternate Title: PROMENE NIVOA CD4+CD25HIGH T ĆELIJA I TGFβ1 U RAZLIČITIM STADIJUMIMA ADULTNOG TIPA 1 DIJABETESA.

المؤلفون: Militic, Tanja¹ icataca@gmail.com, Jotic, Aleksandra¹, Marković, Ivanka², Popadić, Dušan³, Lalic, Katarina¹, Uskokovic, Veljko⁴, Lukic, Ljiljana¹, Macesic, Marija¹, Stanarcic, Jelena¹, Stoiljkovic, Milica¹, Milovancevic, Mina¹, Rafailovic, Djurdja¹, Bozovic, Aleksandra¹, Radisavljevic, Nina¹, Lalic, Nebojsa M.¹

المصدر: Journal of Medical Biochemistry. Nov/Dec2024, Vol. 43 Issue 6, p915-926. 12p.

مصطلحات موضوعية: *INTERLEUKIN-2, *TYPE 1 diabetes, *T cells, *DISEASE remission, *FLOW cytometry, *IMMUNOFLUORESCENCE

المؤلفون: Banc de Sang i Teixits

المصدر: Phase II Randomized Study Evaluating a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer

المصدر: A Phase 1 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of LAVA-051 in Patients with Relapsed or Refractory CLL, MM, or AML

المؤلفون: Recordati UK

المصدر: Combined Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Metastatic or Inoperable Leiomyosarcoma - DiTuSarc Study

المؤلفون: Turnstone Biologics, Corp.

المصدر: A Proof of Concept Study of TBio-4101 (an Autologous Selected and Expanded Tumor Infiltrating Lymphocyte [TIL] Therapy) Using Short-Term Cultured, Selected Autologous TIL Following a Lymphodepleting Chemotherapy Regimen and Followed by IL-2 for Patients With Relapsed or Refractory Melanoma (Phase 1)

المصدر: Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

المصدر: A Phase 1B Study of IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Refractory Primary and Secondary Progressive Multiple Sclerosis

المصدر: Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer

المؤلفون: Masonic Cancer Center, University of Minnesota

المصدر: A Phase I/II Trial in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System
Palmer DC, Guittard GC, Franco Z, Crompton JG, Eil RL, Patel SJ, Ji Y, Van Panhuys N, Klebanoff CA, Sukumar M, Clever D, Chichura A, Roychoudhuri R, Varma R, Wang E, Gattinoni L, Marincola FM, Balagopalan L, Samelson LE, Restifo NP. Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J Exp Med. 2015 Nov 16;212(12):2095-113. doi: 10.1084/jem.20150304. Epub 2015 Nov 2.
Osborn MJ, Webber BR, Knipping F, Lonetree CL, Tennis N, DeFeo AP, McElroy AN, Starker CG, Lee C, Merkel S, Lund TC, Kelly-Spratt KS, Jensen MC, Voytas DF, von Kalle C, Schmidt M, Gabriel R, Hippen KL, Miller JS, Scharenberg AM, Tolar J, Blazar BR. Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. Mol Ther. 2016 Mar;24(3):570-81. doi: 10.1038/mt.2015.197. Epub 2015 Oct 27.
Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, Wunderlich JR, Somerville RP, Rosenberg SA. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015 Dec 11;350(6266):1387-90. doi: 10.1126/science.aad1253. Epub 2015 Oct 29.

المؤلفون: National Cancer Institute (NCI)

المصدر: Phase II Study of MK-3475 in Conjunction With Lymphodepletion, TIL, and High or Low Dose IL-2 in Patients With Metastatic Melanoma

المؤلفون: National Cancer Institute (NCI)

المصدر: A Pilot Study of Lymphodepletion Plus Adoptive Cell Transfer With TGF-Beta Resistant (DNRII) and NGFR Transduced T-Cells Followed by High Dose Interleukin-2 in Patients With Metastatic Melanoma

المصدر: A Phase II Clinical Trial of Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Patients With Metastatic Melanoma

المصدر: Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010 Sep 30;363(14):1324-34. doi: 10.1056/NEJMoa0911123.

المؤلفون: National Cancer Institute (NCI)

المصدر: Phase Ib Clinical Trial of Autologous Anti-NY-ESO-1 TCR-Engineered T Cells in Patients With Relapsed/Refractory Locally Advanced or Metastatic NY-ESO-1-Expressing Triple Negative Breast Cancer

المؤلفون: Swim Across America, Benjamin Gilkey Fund, Cannonball Kids' Cancer Foundation

المصدر: Tumor Infiltrating Lymphocytes in Pediatric Malignant Solid Tumors: A Prospective Biobanking Study and Phase I Clinical Trial

المساهمون: Maximilian Stahl, MD, Principal Investigator

المصدر: A Phase 1 Study of Cytokine-induced Memory-like (CIML) NK Cells With Venetoclax as Consolidation Therapy in AML

المؤلفون: Clinigen, Inc.

المصدر: A Phase II Study of High Dose Bolus IL2 in Combination With Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy

المؤلفون: Merck Sharp & Dohme LLC, Prometheus Laboratories

المصدر: Coordinated High Dose Interleukin-2 (Aldesleukin, Proleukin™) and Pembrolizumab (Anti-PD1, Keytruda™) for Therapy of Metastatic Kidney Cancer

المصدر: COordinated Nivolumab and IntraperiToneal IL-2 for Gastric CanceR with PeritOneaL Metastasis (CONTROL) Phase 1b Pilot Study